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Abstract
Circulating tumour DNA (ctDNA) detection and monitoring have enormous potential clinical utility in oncology. We
describe here a fast, flexible and cost-effective method to profile multiple genes simultaneously in low input cell-free
DNA (cfDNA): Next Generation-Targeted Amplicon Sequencing (NG-TAS). We designed a panel of 377 amplicons
spanning 20 cancer genes and tested the NG-TAS pipeline using cell-free DNA from two HapMap lymphoblastoid cell
lines. NG-TAS consistently detected mutations in cfDNA when mutation allele fraction was > 1%. We applied NG-TAS to
a clinical cohort of metastatic breast cancer patients, demonstrating its potential in monitoring the disease. The
computational pipeline is available at https://github.com/cclab-brca/NGTAS_pipeline.
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Background
Cell-free DNA (cfDNA) in plasma was first analysed in
cancer patients nearly 50 years ago [1]. A fraction of
cfDNA was shown to carry mutations found in the
matched tumour and designated circulating tumour
DNA (ctDNA) [1–3]. The utility of ctDNA as a
non-invasive diagnostic, prognostic or predictive bio-
marker in human cancer is now well documented [4–8].
The amount of cfDNA in plasma is usually low, and
the ctDNA fraction is typically only 1–30%; hence, low
mutant allele frequencies have to be detected. Human
cancers are genetically heterogeneous, and mutations
occur infrequently at recurrent hotspots. Therefore, in
most clinical scenarios (e.g. early diagnosis or monitor-
ing of tumour evolution), high sensitivity and the simul-
taneous investigation of multiple gene targets are
desirable features of any ctDNA detection and quantita-
tion method.
There is a range of methods for detecting mutations in
ctDNA, with the target varying from a single nucleotide
variant (SNV) to the whole genome. A widely used
method to detect mutations in ctDNA is digital poly-
merase chain reaction (dPCR) performed in microfluidic
devices or water-in-oil droplet emulsions [9, 10]. Whilst
dPCR is able to detect rare mutations with extremely
high sensitivity, it is restricted by the number of targets
that can be examined in a single reaction [11].
Several sequencing-based approaches have been devel-
oped to incorporate multiple genomic loci, enabling de
novo mutation identification in ctDNA. Previously, we
described Targeted Amplicon Sequencing (TAm-Seq),
* Correspondence: Suet-Feung.Chin@cruk.cam.ac.uk;
carlos.caldas@cruk.cam.ac.uk
†Meiling Gao and Maurizio Callari contributed equally to this work.
1Department of Oncology and Cancer Research UK Cambridge Institute, Li
Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gao et al. Genome Medicine            (2019) 11:1 
https://doi.org/10.1186/s13073-018-0611-9
which utilised 48 primer pairs to identify mutations in
hotspots or selected regions of 6 key driver genes [12].
Whilst TAm-Seq is useful, it is limited to a small num-
ber of targets. Capture-based sequencing methods can
cover a larger number of genes (or the whole exome)
but are costly at the sequencing coverage (> 300) re-
quired to detect allele frequencies ~ 1%.
There are several ready-to-use commercial kits for
ctDNA sequencing, which can cover up to hundreds of
mutation hotspots and many genes. These include Invi-
sion™ (Inivata), Oncomine™ cfDNA assay (Thermo Fisher
Scientific), Guardant360™ (Guardant Health) and Plas-
maSELECT™ (Personal Genome Diagnostics). These
products are expensive and test custom gene panels.
Disturbingly, a recent study comparing the performance
of two of these commercial products (Guardant360™ and
PlasmaSELECT™) in a cohort of plasma samples from
prostate cancer patients revealed poor agreement [13].
Recently, unique molecular barcodes have been devel-
oped to tag each cfDNA template molecule before PCR
amplification in order to reduce the error rate and allow
robust detection of rare mutant alleles in ctDNA [14].
In summary, using current ctDNA profiling method-
ology, the detection of mutations in a good number of
cancer genes with sufficient sensitivity and in a
cost-effective way poses significant challenges. Here, we
describe a new method for the profiling of ctDNA, des-
ignated Next Generation-Targeted Amplicon Sequencing
(NG-TAS), with several unique features: (i) optimised
for low input ctDNA; (ii) high level of multiplexing, en-
abling the analyses of multiple gene targets; (iii) a be-
spoke computational pipeline for data analysis; and (iv)
very competitive costing. NG-TAS is designed to be flex-
ible in terms of the choice of gene targets and regions of
interest; thus, it can be tailored to various cancer types
and clinical contexts.
Methods
Patient samples and blood processing
Patients were recruited from three different centres
including Cambridge University Hospital, Netherland
Cancer Institute (NKI) and Vall d’Hebron Institute of
Oncology (VHIO). Metastatic breast cancer patients
with hormone receptor-positive tumours were recruited
as a part of a clinical trial (patient number = 30, plasma
samples number = 366). Blood samples were collected in
EDTA tubes and processed within 1 h to prevent
lymphocyte lysis and fragmentation. Samples were cen-
trifuged at 820g for 10 min at room temperature to sep-
arate the plasma from the peripheral blood cells. The
plasma was further centrifuged at 1400g for 10 min to
remove the remaining cells and cell debris. The plasma
was stored at − 80 °C until DNA extraction. This study
was approved by the regulatory and ethics committees at
each site, and the reference number is NCT02285179
(https://clinicaltrials.gov/ct2/show/NCT02285179). All
human samples used were collected after informed con-
sent, and the study was fully compliant with the Helsinki
Declaration.
DNA extraction from plasma and buffy coat
Plasma DNA was extracted between 2 and 4ml of
plasma with the QiaSymphony according to the manu-
facturer’s instruction using Qiagen circulating DNA ex-
traction kit. DNA was isolated from the buffy coat
samples using DNeasy Blood & Tissue Kits (Qiagen).
Generation of cfDNA from NA12878 and NA11840
As previously reported [15], two lymphoblastoid cell
lines, NA12878 and NA11840 from the Human Genome
Diversity Project (HGDP)-CEPH collection, were ob-
tained from the Coriell Cell Repository. A catalogue of
highly accurate whole genome variant calls and homozy-
gous reference calls has been derived for sample
NA12878 by integrating independent sequencing data
and the results of multiple pipelines (http://www.illumi
na.com/platinumgenomes). NA11840 cell line was
chosen from a set of 17 available CEPH cell lines in our
laboratory as it shared the least number of SNPs with
NA12878, to generate the maximum number of virtual
somatic SNVs.
The cell lines were grown as a suspension in RPMI
1640-Glutamax (Invitrogen) supplemented with 10%
foetal calf serum, 5% penicillin and streptomycin at 37 °C
and 5% CO2. The media that the cell lines were grown in
were collected when cells were passaged. The media were
centrifuged at 1500 rpm for 10min at 4 °C to remove cells
and cellular debris. The clarified media were stored at −
20 °C until required. Cell-free DNA was extracted from
the thawed media using the Qiagen circulating DNA ex-
traction kit (Qiagen) according to the manufacturer’s in-
structions and quantified using Qubit High Sensitivity
DNA quantification kit (Life Technologies). DNA from
both cell lines was diluted to obtain 50 ng/μl stock con-
centrations. To generate the serial dilutions of one cell line
with the other, we mixed by volume to obtain the percent-
age (volume/volume) as presented in Additional file 1:
Table S1 (n = 12).
Platinum variant calls for sample NA12878 (the virtual
‘tumour’) and confident regions (high confidence homo-
zygous reference regions plus platinum calls) [16] were
downloaded from http://www.illumina.com/platinumg
enomes. Genotype data for sample NA11840 (the virtual
‘normal’) was obtained from the 1000 Genomes website.
Platinum calls were intersected with our NG-TAS panel
target regions, and variants shared with the NA11840
sample were excluded. Five platinum calls were covered
theoretically by our NG-TAS panel; however, one was
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targeted by one of the amplicons showing no coverage;
therefore, four SNVs were considered as identifiable
‘somatic variants’.
NGS library construction
NGS libraries were prepared from 3 to 5 ng of cfDNA
using the ThruPLEX® Plasma-seq kit (Rubicon Genom-
ics, USA) as described in the manufacturer’s instruc-
tions. NGS library was quantified using qPCR KAPA
Library Quantification kit (KAPA Biosystem), whilst the
fragment size and the NGS library yield were measured
with 2200 TapeStation instrument (Agilent).
Digital PCR
BioMark system from Fluidigm has been used for
dPCR, and the analyses have been performed as previ-
ously described [17]. As described in the manufacturer’s
instructions, DNA samples were mixed with 2× Taq-
Man® Gene Expression Master Mix (Life Technology,
4369016), 20× GE Sample Loading Reagent (Fluidigm,
85000746) and 20× gene-specific assays. The reaction
mix was loaded on the qdPCR 37K™ IFC (Fluidigm,
100-6152). For KRAS (G13D) and AKT1 (E17K) mutant
and wild-type PrimePCR™ ddPCR™ Mutation Assays
were obtained from Bio-Rad (dHsaCP2000013 and
dHsaCP2000014, dHsaCP2000032 and dHsaCP200
0031, respectively). The PIK3CA and ESR1 probes and
primers were previously described [7, 18], and the pri-
mer and probes used are listed in Additional file 1:
Table S2.
NG-TAS protocol
Primer design for NG-TAS
Primers were designed with NCBI Primer-BLAST tool
with Tm range of 59–61 °C. The universal primer se-
quences (CS1 and CS2) were added at the 5′ end of the de-
signed primers. All primer pairs were tested alone and in
multiplexed PCR reactions using 10 ng of TaqMan®
Control Human Genomic DNA (Thermo Fisher Scientific)
in 10 μl reaction volumes. The coverage and performance
of primers were analysed using 2200 TapeStation instru-
ment (Agilent) and Hi-seq 4000. The primers were
grouped together as 7-8plex, and primers in each group
were chosen to target different genes in order to minimise
non-specific amplification and cross-reactivity.
Access Array™ microfluidic system
The 377 pairs of optimised primers were divided into 48
wells, with each well containing 7–8 pairs of primers for
multiplexed PCR. Primers were diluted to the final con-
centration of 1 μM to make 20× primer solution. Four
microlitres of the 20× primer solution from the 48 wells
was added to the primer inlets of the Access Array™ IFC
(Fluidigm). For the sample inlets, pre-sample master mix
consisted of 2× Master Mix (Qiagen, 206143), 5× Q so-
lution, 20× Access Array™ Loading Reagent (Fluidigm),
and DNA sample was added. The loaded IFC then
moved to FC1™ Cycler (Fluidigm) for thermal cycles: 95 °C
for 15min, 30 cycles of 94 °C for 30 s, 59 °C for 90 s, 72 °C
for 90 s and a final extension step 60 °C for 30min. The
reaction products were harvested using post-PCR IFC
controller as described in the manufacturer’s instructions.
The harvested product was diluted (1:10) with water
for further barcoding PCR. Barcoding PCR reaction
master mix contains 2× Master Mix (Qiagen), a diluted
harvested product from Access Array™, and Access
Array™ Barcode Library for Illumina® Sequencers single
direction for barcoding primers (Fluidigm, 100-4876).
The thermal cycle for barcoding is 95 °C for 10 min, 15
cycles of 95 °C for 15 s, 60 °C for the 30 s, 72 °C for 1
min and a final extension step of 72 °C for 3 min. The
PCR reaction was performed using T100™ Thermal Cy-
cler (Bio-Rad).
Quantification and clean-up of barcode Access Array™ harvest
After barcoding PCR, all samples were analysed using
2200 TapeStation (Agilent) to measure the concentration
and size of the products (average 260 bp). The PCR
products were pooled and cleaned with AMPure XP
beads (Beckman Coulter, A63880) following the manu-
facturer’s instruction. Briefly, the samples were mixed
with the magnetic beads to the ratio of 180:100 in vol-
ume. The beads were washed twice with 80% ethanol
and dried by incubating at 30 °C for 10 min. Then, the
beads were eluted with water, and the cleaned PCR
product was run on the E-Gel® 2% agarose gel (Thermo
Fisher Scientific, G501802) for further size selection and
extraction. The band between 200 and 300 bp was cut
out, and DNA was isolated from the gel using the QIA-
quick Gel Extraction kit (Qiagen, 28704), and 10–20 nM
of the eluents was submitted for paired-end Hi-seq 4000
for sequencing.
Analysis of NG-TAS data
Quality control, alignment and BAM files annotation
For each sequencing lane, quality control of raw data
was performed using FastQC (http://www.bioinforma
tics.babraham.ac.uk/projects/fastqc/). Up to 384 samples
were multiplexed in a single sequencing lane and demul-
tiplexing was performed using in-house software.
Alignment, read trimming (at 80 bp) and base quality
recalibration was performed in a single step using
Novoalign (v 3.08). However, to facilitate a broad use of
the pipeline, a version using BWA-MEM is also avail-
able. Alignment and BAM metrics were computed using
Picard Tools (v 2.17). To remove potential off-target
PCR products, only reads mapped in a proper pair and
with insert size > 60 bp were retained. After this filtering,
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BAM files were locally realigned using the Genome Ana-
lysis Toolkit (GATK, v 3.6). Reads were then assigned to
the amplicon they belonged to using a custom javascript,
in order to enable a per amplicon coverage and mutation
calling analysis. Coverage was computed for each ampli-
con in each sample using a custom java/R script. One
amplicon (SF3B1_D0069_001) showed an extremely high
rate of mismatches and indels in all the analysed samples;
therefore, we excluded it from downstream analyses.
Mutation calling
Mutation calling was run separately for each amplicon
in the panel. The core mutation calling was performed
for each pair of plasma and normal samples (or
NA12878 an NA11849 from the dilution series) using
Mutect2 (included in GATK 3.6). The minPruning par-
ameter was set at 5 to reduce computational time with
no significant impact on the results. Besides the set of
mutations passing all internal filters, we included those
failing the following internal filters or a combination of
them: ‘alt_allele_in_normal’, ‘clustered_events’, ‘homolo-
gous_mapping_event’ and ‘multi_event_alt_allele_in_-
normal’. On this set of candidate mutations, we applied
the following filtering criteria: coverage in normal and
plasma > 100×, alternative allele in normal < 1% and
plasma/normal VAF ratio > 5. The core mutation calling
was repeated for the three replicates generated for each
pair, and only mutations called in at least two replicates
were retained. For this set of mutations, we run Haploty-
peCaller (included in GATK 3.6) to compute the average
VAF across the three replicates and filter out mutations
with an average VAF < 1% and an average plasma/normal
ratio < 5 (Fig. 4a). An extra filter was introduced for
FFPE samples, where C>T and G>A transitions with
VAF < 15% were filtered out because likely to be a conse-
quence of cytosine deamination caused by fixation.
In calling somatic mutations from a set of longitudinal
samples from the same patient, we first repeated the
above procedure for all samples. Then, HaplotypeCaller
was run again to estimate in all samples the coverage
and VAF of each mutation called in at least one of them.
This was followed by a variant annotation step using
Annovar. Finally, results obtained for all amplicons were
merged to generate a single VCF file. A final filter was
applied at the group level, that is, keeping only muta-
tions that at least in one sample had VAF higher than
5% (Additional file 1: Figure S1).
Results
Optimising targeted deep sequencing in cfDNA by NG-TAS
We designed 377 pairs of primers covering all exons or
hotspots of 20 genes commonly mutated in breast can-
cer (Table 1). To identify the genes or hotspots of inter-
est, we primarily looked at the comprehensive study
carried out in our lab (Pereira et al. Nat Comm 2016).
Other genes (e.g. ESR1) were included because reported
as frequently mutated in metastasis [19]. Since the aver-
age cfDNA fragment size is 160–170 bp, NG-TAS
primers were designed to generate amplicons of 69–157
bp (Additional file 2).
In a preliminary optimization step, individual primer
pairs were tested in conventional single and multiplexed
(7-8plex) PCR reactions. The NG-TAS experimental
workflow (Fig. 1a), starts with a multiplexed PCR step
(7–8 primer pairs) performed using Access Array™, a
microfluidic system from Fluidigm. Each multiplexed re-
action contained primers targeting different genes to
minimise the generation of unwanted PCR products.
The multiplexed PCR products were assessed using the
Bioanalyser and 2200 TapeStation instrument (Agilent
Genomics; Additional file 1: Figure S2). Multiplexed
PCR products were then pooled and barcoded with 384
unique barcodes in a second PCR reaction. Barcoded
products were pooled and size selected to remove
Table 1 List of genes and regions covered in the panel
Gene Target region Hotspot position No. of amplicons
AKT1 Hotspot E17 4
AA23–59
AA65–94
BRAF Hotspot V600 1
Her2 Hotspot S310 14
AA428–438
AA746–797
AA832–986
HRAS Hotspot AA3–35 (G12 and G13) 3
AA49–77 (Q61 and A66)
IDH2 Hotspot AA 132–162 1
KRAS Hotspot G12 1
SF3B1 Hotspot K700 1
ESR1 Part of exons Exon 8–10 (LBD) 10
SMAD4 Part of exons Exon 8–12 10
CDH1 All exons 46
CDKN1B All exons 9
FOXA1 All exons 18
GATA3 All exons 23
MAP2K4 All exons 22
MAP3K1 All exons 75
PIK3CA All exons 59
PIK3R1 All exons 11
PTEN All exons 24
RUNX1 All exons 24
TP53 All exons 21
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primer dimers before submission for NGS paired-end
150 bp sequencing.
Raw sequencing data were aligned and processed as
described in Fig. 1b and in the ‘Methods’ section. Spe-
cific filters were applied to exclude reads from primer
dimers or other PCR artefacts. Since the amplicons are
partially overlapping, each read was assigned to its re-
spective amplicon, to enable a per-amplicon analysis for
coverage estimation and mutation calling.
To optimise NG-TAS, we used cfDNA isolated from the
culture media of the Platinum Genome HapMap
NA12878 cell line. The size profile of cfDNA isolated
from the tissue culture media was similar to that of
plasma cfDNA (Additional file 1: Figure S3). We tested a
range of input cfDNA amounts with NG-TAS (0.016 to
50 ng) in four replicates for each input. For each cfDNA
input, we tested (i) a pre-amplification step and (ii) the
use of the Qiagen Q solution. To assess the data gener-
ated, the percentage of aligned sequencing reads was com-
puted (Fig. 2a). In the TAM-Seq protocol, addition of a
pre-amplification step reduced the probability of nonspe-
cific amplification and biased coverage [12]. However,
using NG-TAS, the pre-amplification step reduced the
percentage of aligned reads in all cfDNA input samples
tested. Hence, we eliminated pre-amplification from the
NG-TAS protocol. Adding Q solution systematically in-
creased the percentage of aligned reads, with the largest
improvement observed with 0.4 and 2 ng input samples
(Fig. 2a). Thus, we incorporated the Q solution in all sub-
sequent NG-TAS experiments.
We then used the optimised NG-TAS protocol in
triplicate experiments for each input NA12878 cfDNA
(2 ng, 5 ng and 10 ng). With 10 ng of input cfDNA,
NG-TAS generated a median read depth of 3064×, and
only 22/377 amplicons (5.8%) had coverage less than
100× (Fig. 2b). In fact, high amplicon coverage was
observed irrespective of the amount of input cfDNA
(Additional file 1: Figure S4A and S4B). The coverage
heatmap of individual amplicons showed similar patterns
with 10 ng and 5 ng cfDNA input. Strong consistency
was observed within each triplicate (Fig. 2c). However,
with 2 ng cfDNA input, we observed a stochastic reduc-
tion in coverage for some of the amplicons. This is prob-
ably due to a reduction in template availability, with the
number of amplifiable copies approaching zero for some
of the amplicons.
Using these data, the background noise was estimated
by computing the average frequency for non-reference
bases in each position, and for 99% of the targeted gen-
omic positions, background noise was ≤ 0.3% (Fig. 2d).
Fig. 1 NG-TAS workflow and alignment pipeline. a NG-TAS workflow. Primers were designed and multiplexed for direct amplification in cfDNA
obtained from plasma using Fluidigm Access Array™. The PCR products were harvested and barcoded in a subsequent PCR reaction; the samples
were pooled and size selected for sequencing on an Illumina Hi-Seq 4000. b Schematic representation of the computational pipeline for reads
alignment, filtering and annotation
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Sensitivity and specificity of mutation detection in control
cfDNA
To establish an analysis pipeline and assess the perform-
ance of NG-TAS, we generated a benchmark dilution
series, similar to what we have previously described [15],
using cfDNA collected from the tissue culture media
from two lymphoblastoid cell lines from the HapMap/
1000 Genome Project, NA12878 (the Platinum Genome
sample) and NA11840, to mimic a tumour-normal (or
plasma-normal) pair. The dilution series mixed cfDNA
from NA12878 with an increasing amount of cfDNA
from NA11840 (from 0 to 99.8% by volume, n = 12,
Additional file 1: Table S1). This cfDNA dilution series
was used to investigate the sensitivity in detecting
Fig. 2 Optimising targeted deep sequencing by NG-TAS. a Percentage of aligned reads was compared in different samples where a variable
amount of input control genomic DNA was used (range 50 to 0.016 ng). The effect of pre-amplification and Q solutions are shown, red = no Q
solution and no pre-amplification step, green = with Q solution and no pre-amplification, blue = no Q solution and with pre-amplification.
b Density plot showing the log10 coverage values for all primers in the 10 ng NA12878 cfDNA sample. The dotted line indicates 100× coverage;
median value for the distribution is 3064×. c Coverage heatmap of individual primers for a different amount of input NA12878 cfDNA. For each
amount of input DNA, the analysis was performed in triplicate. d Distribution of all non-reference base frequencies across all target regions in the
NA12878 dilution series in c; the smaller plot on the right is a magnification of the main plot between 0 and 0.01
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mutations at high and low allele frequency (50–0.1%).
The 377-amplicon panel encompassed four heterozygous
single nucleotide polymorphisms (SNPs) present only in
NA12878. These SNPs were used as ‘somatic’ mutations
for the purpose of this analysis.
Using NG-TAS, the cfDNA dilution series was tested
in triplicate, varying the input cfDNA from 5 to 50 ng.
Since in clinical plasma samples the amount of ctDNA
is frequently a limiting factor, we also tested the Thru-
Plex plasma-seq kit (requiring as little as 3 ng of cfDNA
input) to generate a whole genome cfDNA library
(termed NGS cfDNA library). An aliquot of this NGS
cfDNA library was then used as input for NG-TAS.
These NG-TAS experiments showed a strong linear
relationship between the observed and expected variant
allele frequencies (VAF) for the four ‘somatic’ mutations
(Table 2, Fig. 3). As the input cfDNA reduced from 50
to 5 ng, the R2 values decreased from 0.968 to 0.885.
With 10 ng input cfDNA, VAFs as low as 1% could be
consistently detected. Lowering the input cfDNA gener-
ated more variable results (i.e. VAF deviating from the ex-
pected values and higher standard deviations), in
particular at low AF. This is probably caused by stochastic
amplification of the alternative allele. NG-TAS performed
using NGS cfDNA library as input performed better than
5 ng of cfDNA input (R2 = 0.964, Table 2, Fig. 3).
The NG-TAS analysis pipeline was developed and
optimised using this dilution series data and later ap-
plied to data from clinical plasma samples. As illustrated
in Fig. 4a and in the ‘Methods’ section, mutation calling
was performed using MuTect2, processing each ampli-
con individually. To limit the number of false positives
(FPs) caused by PCR errors, we only called mutations
observed in at least two out of three replicates. With the
reported settings and using 10 ng of input cfDNA from
the dilution series, all four SNVs were called when the
expected VAF was 5% or higher, and three of four SNVs
when the expected VAF was 1% (Fig. 4b). No FPs with
VAF higher than 3% were called with 50 ng and 10 ng in-
put cfDNA from the dilution series. NG-TAS of both
the 5 ng cfDNA input and NGS cfDNA library input
generated seven FPs above 3% in the dilution series
(Fig. 4c). Template scarcity and extra PCR cycles during
library preparation could explain this increase in FPs.
Therefore, for NG-TAS in plasma samples, we recom-
mend the use of 10 ng cfDNA per replicate as input and
a threshold of 5% VAF for de novo mutation calling. In
plasma samples with less cfDNA, the use of NGS cfDNA
library as input for NG-TAS enables ctDNA profiling in
samples with as little as 3 ng of cfDNA. However, this
approach is more suitable for tracking in plasma ctDNA
mutations previously identified in the tumour, rather
than for de novo plasma ctDNA mutation calling.
Testing NG-TAS performance in cancer patient samples
We applied NG-TAS to a clinical cohort of 30 metastatic
breast cancer patients from which we have collected 360
plasma samples (for 31 of these NGS cfDNA library
samples were used) and buffy coats. This cohort is part
of a clinical trial which will be comprehensively reported
in a separate manuscript (Baird et al. in preparation).
To estimate the FP rate in blood samples, we used
pairs of DNA extracted from the buffy coats collected at
two different time points from four patients. Any muta-
tion identified by NG-TAS in any of the eight possible
buffy coat DNA pairs tested was considered a FP.
Figure 5a shows that in these samples, NG-TAS identi-
fied no FP with VAF greater than 5% (a result similar to
NG-TAS performed using the cell line cfDNA dilution
series, Fig. 4c).
In 24 of the cases in our cohort, at least 1 tissue sam-
ple was also available and analysed. Sixteen of these
cases had tissues from the primary tumour whilst in the
remaining 8 cases, tissue samples were obtained from
metastasis biopsies collected during the trial. Overall, we
found at least 1 mutation in 21/24 patients (87.5%,
Fig. 5b). Forty-four mutations were detected in the tissue
samples and 60 in at least 1 plasma sample; of these, 23
were observed in both tissue and plasma. The agreement
was higher for the 8 cases where a metastasis biopsy was
sequenced: 7 mutations detected in the tissue, 11
detected in plasma and 7 in common (100% of tissue
mutations detected in plasma). In the 16 cases where a
primary tumour was tested, 33 mutations were detected
in the tissue, 41 in plasma and 19 in common (58% of
tissue mutations detected in plasma, Fig. 5b and
Additional file 1: Figure S5). The discordance seen in
this cohort is probably due to the time gap between the
primary tumour tissue sample and plasma, the latter
obtained when the patients had metastatic disease. In
addition, most of the tissue samples were formalin-fixed
paraffin-embedded (FFPE); hence, we detected an in-
crease of C>T/G>A SNVs not usually found in ctDNA
samples (Additional file 1: Figure S5).
We used dPCR to validate a subset of the mutations
identified in seven patients in which NG-TAS was per-
formed either directly on cfDNA (n = 4) or using
post-NGS library products (n = 3). In the four direct
NG-TAS samples, four hotspot mutations PIK3CA
(H1047R and E545K), KRAS (G13D), ESR1 (D538G) and
Table 2 Linear regression analysis for different cfDNA input
Input DNA R2 Estimated coefficient 2.5% CI 97.5% CI
50 ng 0.968 1.075 1.018 1.133
10 ng 0.940 1.005 0.930 1.080
5 ng 0.885 0.932 0.832 1.032
Library 0.964 1.123 1.059 1.187
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Fig. 3 Detection of SNVs in NA12878 cfDNA dilution series. a Expected versus observed VAF for four SNVs in the NA12878-NA11840 dilution
series starting from 50 ng input DNA (left) and zoom-in for expected VAF < 5% (right). b Expected versus observed VAF for four SNVs in the
NA12878-NA11840 dilution series starting from 10 ng input DNA (left) and zoom-in for expected VAF < 5% (right). c Expected versus observed
VAF for four SNVs in the NA12878-NA11840 dilution series starting from 5 ng input DNA (left) and zoom-in for expected VAF < 5% (right).
d Expected versus observed VAF for four SNVs in the NA12878-NA11840 dilution series starting from post-NGS library input DNA (left)
and zoom-in for expected VAF < 5% (right)
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AKT1 (E17K) were all validated by dPCR. A good con-
cordance between VAFs estimated by NG-TAS and
dPCR was found (R2 = 0.64, Fig. 5c). In the three patients
where post-NGS library products were used as input,
two PIK3CA hotspots (H1047R and E545K) were also
validated by dPCR, and a high concordance between the
VAFs estimated by NG-TAS and dPCR was observed
(R2 = 0.80, Fig. 5d).
Monitoring response in breast cancer patients using NG-TAS
We report the example of two patients from the above
clinical trial to demonstrate the use of NG-TAS for
metastatic breast cancer disease monitoring. Patients
had clinical monitoring performed as per the trial
protocol using Response Evaluation Criteria in Solid
Tumour (RECIST), version 1.1.
The first patient had RECIST partial response in the
first 28 weeks and progression on day 197. NG-TAS
identified mutations in GATA3 (F431 fs), PIK3CA
(E542K), CDKN1B (N124 fs) and PTEN (137-139del)
(Fig. 6a). PTEN mutation VAFs in ctDNA showed paral-
lel dynamics to RECIST: initial drop, followed by a con-
tinuous rise from day 85, preceding RECIST progression
by over 100 days. The VAFs of the other mutations
showed a parallel rise starting later.
The second patient had stable disease by RECIST
during the 60 days of available follow-up. Due to the
limited amount of cfDNA extracted in this case,
NG-TAS was performed using NGS cfDNA libraries.
Fig. 4 Mutation calling in NA12878 cfDNA dilution series. a Schematic overview of the computational pipeline to identify somatic mutations in
NG-TAS data. b De novo mutation calling in the NA12878 dilution series was evaluated for different amounts of input cfDNA. Four SNVs can
potentially be called using our panel of 377 amplicons. c VAF for all FP calls in the NA12878 dilution series. The red dashed line represents 5% VAF
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NG-TAS detected PIK3CA (H1047R), MAP3K1
(E303fs) and TP53 (R141H and P46fs) mutations, and
their VAFs showed stable values, and then a slight
reduction between days 20–56, followed by a slight
rise by the time monitoring was discontinued
(Fig. 6b).
Fig. 5 Validation of NG-TAS performance in clinical plasma samples. a The specificity of NG-TAS in clinical samples was estimated using 4 pairs of
buffy coats from the same patients (A, B, C and D). The mutation calling pipeline was applied using one buffy coat as normal and the other as
‘tumour’ and vice versa. All mutations called in this setting can be considered FPs. The red line indicates 5% VAF. b Oncoprint summary plot of genes
mutated in 24 cases for which both tissue and plasma samples were tested. The vertical black line separates cases for which the primary tumour was
analysed from cases for which a metastasis biopsy was analysed. c, d Comparison of VAF obtained by NG-TAS and dPCR. c In this comparison, four
different hotspot mutations including AKT1 (E17K), ESR1 (D538G), KRAS (G13D) and PIK3CA (H1047R) identified in multiple plasma samples from 4 distinct
patients were analysed (R2 = 0.64). d Two PIK3CA hotspots (H1047R and E545K) were detected by NG-TAS using NGS library as an input material in
plasma samples from two distinct patients. The same mutations were detected using dPCR, and a good correlation was found (R2 = 0.80)
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These two examples demonstrate the use of NG-TAS
in plasma cfDNA samples to monitor tumour burden in
metastatic breast cancer patients.
Comparison of NG-TAS with other approaches
We finally compared NG-TAS to other existing tech-
nologies such as digital PCR, TAm-Seq and Oncomine™
Breast cfDNA Assay (Table 3). NG-TAS can be per-
formed in 7 h using the Fluidigm system as detailed in
the ‘Methods’ section. Up to 384 samples can be proc-
essed at the same time. Lower limits of detection can be
reached using Digital PCR or Oncomine technology;
however, this is limited to one target for the first and a
set of pre-defined hotspots for the latter. Importantly,
the cost of NG-TAS, estimated at 30 GBP per sample, is
significantly lower than any commercial solution, mak-
ing it cost-effective for use in the clinics.
Discussion
The genes frequently mutated in different human can-
cers have been characterised by large-scale sequencing
studies such as The Cancer Genome Atlas [20, 21].
These pan-cancer studies have revealed that most hu-
man tumours have at least one to ten driver mutations,
allowing the design of custom gene panels that could be
used for generic cancer detection. But the challenge
remaining is there are very few recurrent or hotspot mu-
tations in tumours such as breast cancer, with mutations
spread along the protein coding region, as observed in
TP53, GATA3 and MAP3K1. Therefore, it would be de-
sirable to cover most exons of these genes simultan-
eously in a ctDNA mutation detection panel.
The detection of specific mutations in ctDNA is
achievable by dPCR, now considered the gold standard
to detect mutations with low VAFs. However, dPCR is
constrained by the number of mutations that can be de-
tected in a single reaction [11]. Thus, its high sensitivity
and specificity are at the expense of the number of mu-
tations that can be detected concurrently. At the other
end of the spectrum, whole genome sequencing or
whole exome sequencing suffers from reduced sensitivity
at the current achievable level of sequencing depth [22].
We report here a new approach, NG-TAS, an optimised
targeted amplicon sequencing pipeline that provides clinic-
ally relevant sensitivity in mutation calling across a tar-
geted, but relatively broad and customizable panel of
genes. The current version of NG-TAS covers all exons or
hotspots of 20 breast cancer-associated genes in a total of
377 amplicons, has a lower detection limit of 1% VAF and
requires only three aliquots of 10 ng cfDNA input. The
single step multiplexed PCR amplification makes it a less
time-consuming method and more cost-effective than
other assays, such as the commercially available Oncomine
assay (Table 3). NG-TAS is flexible and custom designed
primers can be adjusted to the needs of the end user, de-
pending on the cancer type and the clinical context.
Importantly, we developed a bespoke NG-TAS compu-
tational pipeline for data analysis, with all the relevant
open-source code available at GitHub (https://github.
com/cclab-brca/NGTAS_pipeline). All sequencing data
are also made available at https://figshare.com/articles/
NGTAS_NA12878/7387370 and https://www.ebi.ac.uk
(EGAS00001003392). These will be instrumental to test
and further develop the computational pipeline, as re-
quired by regulatory agencies.
Fig. 6 Monitoring response in metastatic breast cancer patients using NG-TAS. a Example of patient monitoring during treatment using direct
NG-TAS in ctDNA. There are four mutations detected in more than one sample: GATA3 (F431 fs), PIK3CA (E542K), CDKN1B (N124 fs) and PTEN
(137-139del). The mutations called more than once in the longitudinal samples are shown including the tumour and plasma samples. The arrow
indicates the time of the disease considered as RECIST progressive disease. T indicates tumour samples, and SP indicates screening plasma
sample which was collected prior to the treatment. b Example of patient monitoring during treatment using NGS library material for NG-TAS. This
patient had a stable disease during the whole treatment period. There are three mutations detected, including MAP3K1 (E303 frame shift), hotspot
mutations PIK3CA (E545K) and TP53 (R141H and P46fs). T indicates tumour samples
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The custom design of primers for NG-TAS is po-
tentially challenging. Building a customised panel of
primers manually, using the tool mentioned above is
time-consuming and, in some cases, difficult due to
genomic sequence context (e.g. high GC and repeti-
tive regions). The multiplex PCR requires a fixed an-
nealing temperature, but more complex PCR cycle
design can circumvent this. Nevertheless, we were
able to design primers that yielded in 94% of ampli-
cons over 100× coverage (Fig. 2b). We provide all pri-
mer sequences (Additional file 2), and an open source
optimised primer library will be growing with an
NG-TAS user community.
When using NG-TAS for accurate estimation of
VAF, as required to do serial tumour burden monitor-
ing, our data suggests that at least 10 ng of input
cfDNA per replicate is required. NG-TAS has poor
performance with cfDNA input below 5 ng (per repli-
cate), with amplicon coverage reduced in a stochastic
manner, probably due to the limited availability of
template. A suitable alternative protocol for these
cases is to generate an NGS cfDNA library, requiring
only 3 ng of cfDNA, and use the library material as
input for NG-TAS.
We applied NG-TAS to a cohort of 30 patients for
which both tissue and serial plasma samples were
available. The percentage of mutations identified in
tissue and detected in ctDNA was 100% when the tis-
sue was from a synchronous metastasis biopsy and
58% when the tissue was from the primary tumour.
Such an agreement is higher than what recently re-
ported by Chae et al. [23]. In their cohort of 45 pa-
tients, 60% of tissue samples were from primary
tumours, and 58% of the tissues were acquired more
than 90 days before ctDNA testing. The Foundatio-
nOne panel was used for tissue analysis and the
Guardant360 assay for ctDNA. They detected only
25.6% of tissue mutations in plasma when evaluating
the common regions between the two targeted
approaches.
A future development of NG-TAS will be the use of
molecular barcoding since this has been shown to im-
prove sensitivity and specificity of amplicon-based
deep sequencing [24]. This will have cost implica-
tions, potentially limiting one of the main advantages
of the current NG-TAS protocol. The extra costs
would be the result of the generation of barcoded
primers. For example, if 96 distinct barcodes are used,
the primer cost will increase around 100 times. How-
ever, costs will be significantly diluted when consider-
ing laboratories processing a large number of
samples, keeping the overall cost of NG-TAS within a
very reasonable range.
Conclusions
We have described here the workflow for a highly multi-
plexed cfDNA deep sequencing method named
NG-TAS. NG-TAS assesses the mutational status of sev-
eral genes simultaneously, with high sensitivity (allowing
quantification of AF) and competitive costs, and offers
flexibility in the choice of target genes. We have also
shown proof of principle that the monitoring of ctDNA
using NG-TAS in metastatic breast cancer can allow de-
tection of cancer progression earlier than conventional
RECIST measurements.
Table 3 Comparison of different approaches for ctDNA detection
NG-TAS Digital PCR TAm-Seq Oncomine™ Breast cfDNA Assay
Approx. cost per sample (GBP) 3 × 10 2–3 10 200
Time (96 reactions) 7 h 3 h × 2 2 days 2 days
Number of amplicons 377 1 48 n/a
Amplicon size (bp) < 160 n/a < 200 < 170
Number of genes 20 1 (hotspot) 6 10
Choice of targets Flexible Limited Flexible Limited
Median depth 3064 770 650 (avg) n/a
Limit of detection (%) 1–2 > 0.1 1–2 0.6–0.1
Library material as input Yes Not tested Not tested Not tested
Ideal input (ng) 3 × 10 2–5 50 20
Multiplex 8plex No No n/a
Number of samples per sequence run 384 n/a 96 12
Platform Fluidigm Access Array Fluidigm qdPCR Fluidigm Access Array Ion Chef System
Sequencing Illumina HiSeq 4000 n/a Illumina GAIIx Ion S5/S5XL™
Gao et al. Genome Medicine            (2019) 11:1 Page 12 of 14
Additional files
Additional file 1: Figure S1. Schematic overview of the computational
pipeline to identify somatic mutations in NG-TAS data from longitudinal
samples. Figure S2. Representative image of the Bioanalyser gel plot. The
8plex PCR products were analysed using Bioanalyser for primer efficiency
and quality control. Figure S3. Fragment size distribution according to
the Bioanalyser results for cfDNA extracted from the media where
NA12878 cells were grown (main peak at around 160-170bp). Figure S4.
(A) Percentage of amplicons having more than 100x coverage for 2, 5
and 10 ng of input cfDNA from NA12878 sample. (B) Percentage of reads
on target for 2, 5 and 10 ng of input cfDNA from NA12878 sample.
Figure S5. Detailed representation of mutations identified in tumour or
plasma samples of 21 metastatic breast cancer cases. The colour gradient
indicates the VAF as indicated; PT = primary tumour, M = metastasis
biopsy, V1…n = plasma. Table S1. The proportion of NA12878 and
NA11840 for the generation of the cfDNA dilution series with expected
VAF. Table S2. Primers and Probes for PIK3CA and ESR1 hotspot
mutations for digital PCR. (PDF 705 kb)
Additional file 2: List and description of the 377 primers used. (XLS 208 kb)
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